KidsGenomics was established in February 2018 by Dan Koboldt, a genetics researcher at The Institute for Genomic Medicine at Nationwide Children’s Hospital in Columbus, Ohio. His research aims to discover new genes and mutations underlying pediatric disease using massively parallel sequencing and other state-of-the-art genomics technologies.
During his 13-year tenure at Washington University in St. Louis, Dan maintained the MassGenomics blog, which discussed next-gen sequencing, genetics, and genomics in the post-genome era. KidsGenomics will instead focus on genetic diseases that affect children, including rare inherited disorders and pediatric cancers.
You can follow Massgenomics and be updated when new content is posted in a few different ways:
- Subscribe by e-mail, which is free and the fastest way to learn when new articles are posted. Use the form to the right.
- Follow by RSS, which provides a feed of all posts on Kidsgenomics.
- Follow on Twitter, to see new articles as well as relevant shorter updates.
The views expressed on this site, including blog posts and static pages, do not necessarily reflect the opinions of the Institute of Genomic Medicine, Nationwide Children’s Hospital, or The Ohio State University.
Dan Koboldt has received royalty income from several private entities that have licensed VarScan, his variant caller for next-gen sequencing data. These include:
- Appistry, Inc.
- Bina Technologies
- Cancer Genetics, Inc
- Fera Science Limited
- GRAIL Inc.
- Human Longevity
- Janssen Research & Development, LLC
- Maverix Biomics
- Natera Inc.
- Pfizer Inc.
- Philips Electronics North America
- Regeneron Pharmaceuticals, Inc.
- Stanford Healthcare
- Syngenta Crop Protection, LLC